Status:
ACTIVE_NOT_RECRUITING
Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Hepatocellular Carcinoma
Liver Cirrhosis
Eligibility:
All Genders
18+ years
Brief Summary
Following the results of the randomized clinical trial IMbrave150, the combination of Atezolizumab with Bevacizumab became the first line regimen for patients with advanced hepatocellular carcinoma an...
Detailed Description
Following the results of the randomized clinical trial IMbrave150, the combination of Atezolizumab with Bevacizumab became the first line regimen for patients with advanced hepatocellular carcinoma an...
Eligibility Criteria
Inclusion
- patients with liver cirrhosis (Child Pugh A or Child Pugh B) and advanced HCC eligible for systemic therapy
- radiological or histological diagnosis of HCC
- age \> 18 years old
Exclusion
- age \< 18 years old
- patients without HCC or with HCC eligible for curative or locoregional treatments
Key Trial Info
Start Date :
July 27 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2025
Estimated Enrollment :
741 Patients enrolled
Trial Details
Trial ID
NCT07193316
Start Date
July 27 2023
End Date
October 31 2025
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Agostino Gemelli IRCCS
Roma, Italy, 00168